goamofo

A Lost Hope? Dendreon Derailed While Archaic FDA Promises 'New Era'

Von Eschenbach has no teeth. Why did he direct this to an Advisory Committee it he was going to ultimately deny the application. This coming from a man who is himself a prostate cancer survivor and whose father died of prostate cancer. Do you think that being able to have spent an additional 4.5 months with his father (the Provenge survival benefit) would have been worth it to Von Eschenbach?

What a waste for terminal prostate cancer patients. Clean safety and statisically signifcant survival benefit. Most prostate cancer patients that are ALREADY terminal value quality of life and SURVIVAL greater than whether dubious and toxic chemotherapy is shrinking his tumor.

To wit, this decision is a catastrophy on so many levels. Funding for biotechs like Dendreon? Gone. Provenge availability to prostate cancer sufferers? Sorry, it's not happening.

Regardless of your position on the stock --- long or short --- you cannot deny that this decision means a probable death sentence for 20-some-thousand men per year in the United States. Great, just great.